Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is a well-capitalized biopharmaceutical company working towards developing therapies for serious liver diseases and metabolic disorders. With key candidate pemvidutide in late-stage development for multiple indications, including AUD and ALD, and the company's strong financial position, there is a high potential for pemvidutide to become a successful and commercially viable treatment option. Additionally, upcoming catalysts such as data presentations at EASL 2026 and a potentially earlier completion of enrollment in the ALD trial add further upside potential for the stock.

Bears say

Altimmune is expected to face challenges with the success and commercialization of its key candidate, pemvidutide, due to its limited PoS in AUD and ALD and potential risks associated with clinical development, competition, pricing, reimbursement, and business development. The company also faces potential dilution for existing shareholders with an expected equity capital raise in 2029E. Overall, this assessment leads to a negative outlook for Altimmune's stock due to the uncertainties and risks involved in the company's pipeline and financials.

Altimmune (ALT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 4 analysts, Altimmune (ALT) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.